Back to Search
Start Over
Identification of ligands binding to MB327-PAM-1, a binding pocket relevant for resensitization of nAChRs.
- Source :
-
Toxicology letters [Toxicol Lett] 2024 Jul; Vol. 398, pp. 91-104. Date of Electronic Publication: 2024 May 18. - Publication Year :
- 2024
-
Abstract
- Desensitization of nicotinic acetylcholine receptors (nAChRs) can be induced by overstimulation with acetylcholine (ACh) caused by an insufficient degradation of ACh after poisoning with organophosphorus compounds (OPCs). Currently, there is no generally applicable treatment for OPC poisoning that directly targets the desensitized nAChR. The bispyridinium compound MB327, an allosteric modulator of nAChR, has been shown to act as a resensitizer of nAChRs, indicating that drugs binding directly to nAChRs can have beneficial effects after OPC poisoning. However, MB327 also acts as an inhibitor of nAChRs at higher concentrations and can thus not be used for OPC poisoning treatment. Consequently, novel, more potent resensitizers are required. To successfully design novel ligands, the knowledge of the binding site is of utmost importance. Recently, we performed in silico studies to identify a new potential binding site of MB327, MB327-PAM-1, for which a more affine ligand, UNC0646, has been described. In this work, we performed ligand-based screening approaches to identify novel analogs of UNC0646 to help further understand the structure-affinity relationship of this compound class. Furthermore, we used structure-based screenings and identified compounds representing four new chemotypes binding to MB327-PAM-1. One of these compounds, cycloguanil, is the active metabolite of the antimalaria drug proguanil and shows a higher affinity towards MB327-PAM-1 than MB327. Furthermore, cycloguanil can reestablish the muscle force in soman-inhibited rat muscles. These results can act as a starting point to develop more potent resensitizers of nAChR and to close the gap in the treatment after OPC poisoning.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Animals
Ligands
Binding Sites
Pyridinium Compounds pharmacology
Pyridinium Compounds chemistry
Rats
Structure-Activity Relationship
Male
Protein Binding
Molecular Docking Simulation
Soman
Nicotinic Antagonists pharmacology
Nicotinic Antagonists chemistry
Receptors, Nicotinic metabolism
Receptors, Nicotinic drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1879-3169
- Volume :
- 398
- Database :
- MEDLINE
- Journal :
- Toxicology letters
- Publication Type :
- Academic Journal
- Accession number :
- 38768836
- Full Text :
- https://doi.org/10.1016/j.toxlet.2024.05.013